Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > Chuikyo on FY2024 Reimbursement Reform
Chuikyo on FY2024 Reimbursement Reform
-
Chuikyo Reps Criticize Manufacturers’ Price Cuts after Unprofitability Re-Pricing
August 3, 2023
-
Chuikyo Medical Device Pricing Body Calls for Clearer Reimbursement Criteria for SaMDs
July 27, 2023
-
Chuikyo Wary of Abolishing Spillover Rule, Positive on Reviewing Market Expansion Re-Pricing
July 27, 2023
-
Chuikyo Divided Over Raising Premium Rates for Listed Products, Extending Evaluation Data
July 27, 2023
-
Chuikyo OKs CEA Organization’s Reform Directions for FY2024
July 13, 2023
-
Chuikyo Reps Want More Data from Industry to Review Launch Premiums
July 13, 2023
-
Chuikyo Discusses Price Maintenance Premium, Focus Is on Company Criteria
July 13, 2023
-
Chuikyo Split over Drug Lags and Losses, Rapid Introduction Evaluation System
July 13, 2023
-
Amid High Turnover Rate, JPWA Presses for New System to Support Drug Prices
July 7, 2023
-
Industry Stresses Stronger Price Support Rule to Ensure Stable Supplies
July 7, 2023
-
Reflect Societal Values in Pricing of Regenerative Medicines: FIRM
July 7, 2023
-
JPMA Pushes Simple Price Maintenance for Innovative Meds; PhRMA, EFPIA in Sync
July 6, 2023
-
Discuss Drug Price Revision System That Doesn’t Cause Yakkasa: FPMAJ Chair
July 6, 2023
-
Pharma Groups Float New Methods to Evaluate Innovative Drugs for 2024 Reform
July 6, 2023
-
Japan, US, Europe Trade Groups Urge Japan to Abolish “Spillover” Re-Pricing
July 6, 2023
-
5 FPMAJ-Affiliated Bodies Petition Expanded Coverage, Eased Criteria for Essential Drug Rule
July 6, 2023
-
Chuikyo Kicks Off Debates toward FY2024 Drug Price Reform
June 22, 2023
-
Chuikyo OKs CEA Discussion Timeline for FY2024 Reform; Industry Hearing Set for August, November
April 27, 2023
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…